Atossa Therapeutics
ATOS
8 hedge funds and large institutions have $972K invested in Atossa Therapeutics in 2013 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
523% more capital invested
Capital invested by funds: $156K → $972K (+$816K)
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
167% more funds holding
Funds holding: 3 → 8 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$249K |
| 2 |
Goldman Sachs
New York
|
+$170K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$131K |
| 4 |
Jane Street
New York
|
+$105K |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$26.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$14K |
| 2 |
Citigroup
New York
|
-$1K |
ATOS Hedge Fund Activity: Q3 2013 in Review
8 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q3 2013, worth a combined $972K — up 523% from $156K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATOS positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $249K. The largest seller was Barclays, exiting entirely with an estimated $14K sold.
- 8 institutional investors held Atossa Therapeutics (ATOS) as of Q3 2013, up from 3 in Q2 2013.
- Funds reported $972K of Atossa Therapeutics stock for Q3 2013, up 523% quarter-over-quarter.
- 6 funds opened new Atossa Therapeutics positions in Q3 2013 and 1 closed out, a net change of +5 holders.
- The largest Atossa Therapeutics buyer in Q3 2013 was Invesco, an estimated $249K added.
- The largest Atossa Therapeutics seller in Q3 2013 was Barclays, an estimated $14K sold.
Based on aggregated 13F filings for Q3 2013.